Key Takeaways
- Invisible Labor Costs: An estimated 92% of medical groups have hired or reassigned staff specifically to manage prior authorization volume, turning administrative overhead into a growing operational expense.
- Revenue Bottlenecks: Prior authorization delays slow treatment starts, claims submission, and reimbursement timelines, particularly for high-value biologics, infusion therapies, and specialty medications.
- Patient Drop-Off Risk: Over half of new specialty prescriptions go unfilled, while 17% of patients abandon therapy even after approval due to administrative friction and treatment delays.
- Workflow Fragmentation: Specialty therapies often require practices to manage both medical and pharmacy benefit pathways simultaneously, increasing duplicate documentation, payer coordination, and authorization complexity.
- Timeline Visibility and the Cost Gap: Manual prior authorization transactions can be costly to providers, reinforcing the need for practices to adopt electronic prior authorization (ePA) and track internal lag, payer lag, and fulfillment lag separately to identify where delays are creating the greatest financial strain.
Some specialty practices can tell you roughly how many of their claims were denied last month. Far fewer can tell you how many staff hours disappeared into prior authorization follow-ups, resubmissions, scheduling delays, and payer callbacks.
That awareness gap has real implications, and its effects rarely surface immediately. Instead, the financial impact spreads quietly across the organization: coordinators spending hours chasing approvals, treatments pushed weeks off schedule, referrals that never convert into active therapy, and reimbursement timelines that continue stretching longer after care decisions have already been made.
Prior authorization delays that specialty practices face today create operational leakage across the entire revenue cycle. That drain isn’t a mere denial issue, but rather a symptom of organizations still not measuring where delays occur, how long they last, or what they’re actually costing the practice.
The data paints a clear picture of this constraint. According to the MGMA 2024 Prior Authorization Issue Brief, 92% of medical groups reported hiring or reallocating staff specifically to manage authorization volume. Meanwhile, the 2024 CAQH Index estimated that manual prior authorization transactions cost providers $12.88 per request, compared to a significantly lower cost of just $5.38 through electronic prior authorization (ePA) workflows. For specialty practices, the strain is even higher, as the report notes that specialists spend more time and money handling authorizations due to the complex nature of their services and frequent friction with insurance-side reviewers unfamiliar with their niche field.
When multiplied across hundreds or thousands of authorization requests annually, the operational burden becomes impossible to ignore.
The Costs Hiding Inside Specialty Prior Authorization Workflows
The financial impact of prior authorization delays in specialty practices extends well beyond denied claims. A significant portion of the cost comes from labor, rework, and slowed treatment progression.
Authorization coordinators, nurses, billers, and clinical staff often spend large portions of their day navigating fragmented payer workflows. That includes:
- Following up on pending requests.
- Uploading duplicate documentation across payer portals.
- Correcting incomplete submissions.
- Preparing peer-to-peer review materials.
- Tracking payer status updates.
- Managing appeals and resubmissions.
- Coordinating patient communication during delays.
Every step consumes time that could otherwise support patient throughput or revenue-generating activity. The administrative burden becomes especially pronounced in specialties managing infused therapies, injectable medications, or complex biologics. These specialty drug classes often require layered clinical documentation, medical necessity validation, laboratory records, and site-of-care justification before approval can even begin.
Some medications also create dual-pathway complexity between pharmacy and medical benefits, forcing staff to navigate entirely different authorization structures depending on how treatment is billed.
This workflow fragmentation creates a hidden labor tax across the organization. Denied claims and resubmission costs add a layer of financial waste. According to a 2026 KFF analysis, more than 80% of appealed Medicare Advantage denials are eventually overturned. That means practices frequently spend additional administrative hours reworking requests for treatments that ultimately receive approval anyway.
Then there’s patient abandonment, possibly one of the most overlooked financial consequences of all. According to IQVIA’s 2026 specialty prescription analysis, more than half of new specialty prescriptions go unfilled. Even after insurer approval, 17% of patients abandon therapy because of the cumulative burden surrounding treatment access.
For specialty practices, those patients rarely appear inside denial metrics or reimbursement reports. They simply disappear before therapy begins. The result: lost infusion appointments, missed follow-up care, and lower referral conversion — all of it unreimbursed.
How Long Is Your Practice Actually Waiting? A Simple Way to Find Out
One reason prior authorization delays that specialty practices experience remain difficult to solve is because many organizations lack a consistent way to measure them. And it starts with knowing where those gaps occur.
The table below illustrates how a simple tracking structure might look in practice. Three patient scenarios, each at a different stage of the authorization process, show how lag time accumulates differently depending on where the delay originates.
Sample Wait-Time Tracker
Each column tells a different part of the story. Breaking down the three lag stages individually makes it easier to see where your own workflows may be losing time.
| Patient / Therapy | Order Date | PA Submitted | PA Approved | First Treatment | Internal Lag (Days) | Payer Lag (Days) | Fulfillment Lag (Days) | Potential Revenue at Risk | Delay Driver | Notes / Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| RA Biologic Infusion | March 3 | March 5 | March 14 | March 20 | 2 | 9 | 6 | $8,400 | Payer review delay | Additional labs requested |
| MS Injectable Therapy | March 7 | March 8 | March 11 | March 18 | 1 | 3 | 7 | $5,100 | Scheduling backlog | No infusion slots available |
| GI Specialty Medication | March 10 | March 15 | Pending | — | 5 | Ongoing | — | $6,700 | Internal workflow delay | Missing chart documentation |
Order Date → PA Submission
This gap reflects internal process lag.
Delays here often point toward staffing shortages, incomplete intake workflows, unclear authorization ownership, or documentation bottlenecks between clinical and administrative teams.
Every additional day delays reimbursement before the payer review process has even started.
PA Submission → PA Approval
This reflects payer delay.
Long prior authorization turnaround times may indicate payer-specific friction, incomplete documentation, repeated follow-up requirements, or avoidable submission errors.
For many specialty practices, this stage creates the largest concentration of administrative workload and uncertainty around treatment timing. According to the 2024 CAQH report, staff lose an average of 24 minutes processing a single manual request, and even web portals consume 16 minutes — the heaviest portal lag across all healthcare administrative transactions.
PA Approval → First Treatment
This reflects fulfillment lag.
Approvals may already be secured, but treatment can still stall due to infusion chair availability, scheduling coordination, staffing limitations, inventory management, or patient communication breakdowns.
Some practices focus heavily on insurance approval delays while overlooking operational delays occurring after authorization is complete. Each stage represents a separate revenue bottleneck.
What the Numbers Can Tell You About Insurance Approval Delays and Billing Impact
Once practices begin tracking these timelines consistently, patterns typically emerge quickly. Some organizations discover the largest issue is internal process lag. Authorizations may sit for several days before submission because staff are overloaded or workflows rely too heavily on manual coordination.
Others identify payer delay as the primary bottleneck. Certain plans consistently require more documentation, longer turnaround times, or higher rates of peer-to-peer review before approval. Some practices uncover a fulfillment problem instead. Approvals arrive, but scheduling and treatment initiation continue lagging behind.
These distinctions matter because each delay category affects revenue differently.
A practice facing internal lag may be slowing reimbursement through workflow inefficiency, while another experiencing payer bottlenecks may be absorbing unnecessary administrative cost through fragmented authorization management. On the other hand, a practice sitting on approved treatments may have a throughput and scheduling problem rather than an authorization problem.
Without measurement, all three issues often appear identical financially: slower cash flow and delayed revenue realization.
This is why prior authorization delays in specialty practices should be evaluated as a timeline problem rather than solely a denial problem. Using a tracker creates something many organizations currently lack: operational visibility into where reimbursement timelines are expanding and why.
Prior Authorization Delays: Revenue Gaps in Disguise
Most specialty practices already recognize prior authorization as an administrative burden. The larger issue is understanding how much financial drag those delays create across the organization.
The impact extends beyond denials, stretching to staff labor, delayed reimbursement, patient abandonment and treatment dropout, scheduling inefficiency, and referrals that never fully convert into active therapy.
Tracking wait times helps you build a baseline for understanding how prior authorization delays that specialty practices encounter affect revenue timing and operational performance, improving specialty practice revenue cycle management in turn.
CareTria Provider Connect helps specialty practices reduce fragmentation across authorization workflows while supporting fast benefit investigation turnaround times and high prior authorization approval rates. That directly compresses the timeline between physician order and treatment initiation — the exact timeline many practices are only beginning to measure closely.
To learn how CareTria Provider Connect can help reduce authorization-related delays, contact our team.
FAQ: Prior Authorization Delays in Specialty Practices
Why are prior authorization delays so costly for specialty practices?
Specialty therapies often involve high-cost medications, extensive documentation requirements, and multiple approval workflows. Delays affect staffing, scheduling, reimbursement timing, and patient retention simultaneously.
What hidden costs are associated with prior authorization workflows?
Hidden costs include staff follow-up time, duplicate data entry, payer communication, peer-to-peer preparation, appeals, resubmissions, and patient abandonment during extended approval timelines.
How can specialty practices measure authorization delays?
Practices can track milestones including physician order date, submission date, approval date, and treatment initiation date to identify where operational bottlenecks occur.
How do prior authorization delays affect revenue cycle management?
Authorization delays postpone treatment starts, delay claims submission, slow reimbursement, and can reduce overall referral conversion into active therapy.
Why do patients abandon specialty therapy during authorization delays?
Long wait times, repeated administrative hurdles, insurance uncertainty, and treatment access frustration can lead patients to discontinue the process before therapy begins.
